Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0005684 (bladder cancer)
 16,431 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred and three patients with moderate and severe cancer pain were given a sublingual analgesic agent--dihydroetorphine hydrochloride (DHE). Relief of cancer pain was moderate or complete in 89.3% (92/103). The average relief time (ART) was 3.9 hours and the average time before effectiveness was 20 minutes. In patients with acute or chronic cancer pain, moderate and complete pain-relief rates were 91.3% and 82.2% (P = 0.237). Difference of ART between them was insignificant (P = 0.299). The main clinical side-effects were somnolence (60%), dizziness (72%), nausea (30%), vomiting (16.5%), constipation (5%) and shortness of breath (8%). In two of the patients, the administration of DHE had to be stopped due to its side-effects. Age, sex and site of cancer pain were not related to the analgesic effects of DHE, but the pain-relief in patients with bladder cancer was poor (P less than 0.001). Within certain range, increase in dose was able to enhance its analgesic effect (P less than 0.001) and reduce drug resistance (P less than 0.001).
 ...
PMID:[Dihydroetorphine hydrochloride for moderate and severe cancer pain]. 188 41

Although it is common to find metastases of transitional cell carcinoma of the bladder to the lymph nodes, lung, bone, and liver, cardiac metastases have only been rarely reported. We report a case of symptomatic metastasis of transitional cell cancer to the right ventricle. A 59-year-old man with a history of transitional cell bladder cancer status post cystectomy and chemotherapy, with neobladder placement, presented with hematuria, shortness of breath, murmur, and evidence of right-sided heart failure. On imaging workup, including transthoracic echocardiography and cardiac computed tomography, we found a large right ventricular mass. A review of the literature showed that there are only 9 cases of cardiac metastasis from transitional cell cancer reported; however, our case is unique because it is the only reported case of symptomatic improvement due to effective treatment with chemotherapy.
 ...
PMID:A rare case of successfully treated cardiac metastasis from transitional cell bladder cancer. 2143 64

Endobronchial metastasis of urinary bladder cancer is rare. A 71-year-old man presented with shortness of breath and cough. He was diagnosed with prostate adenocarcinoma and transitional cell carcinoma of the urinary bladder in the past. Bronchoscopy identified grape-like endotracheal lesions clustering over the distal tracheal wall obstructing 50% of the tracheal lumen and causing an almost complete obstruction of the left main bronchus. There was also extrinsic compression of the left main bronchus along with patchy nodular tumoral lesions involving the right main and the intermediate bronchial walls. Histologic examination of the lesions showed endobronchial metastasis from the bladder cancer. Bronchoscopy is a highly valuable method for evaluating the uncommon endobronchial metastases. Therapeutic bronchoscopy in such cases can contribute to improving quality of life and may impact the survival of the patient. Our patient survived for 5 months after a therapeutic bronchoscopy.
 ...
PMID:Endobronchial metastasis from transitional cell carcinoma of the urinary bladder. 2316 86

Idiopathic pulmonary fibrosis is a rare disorder due to progressive, widespread fibrotic damage of the lung parenchyma. It usually occurs after the age of 50, and its cause is unknown. Symptoms include progressive shortness of breath and nonproductive cough. The course of the disease is marked by exacerbations. Death from respiratory failure occurs about 2 to 5 years after diagnosis. There are currently no drugs that can control or slow the fibrotic process. Pirfenidone, an immunosuppressant, has been authorised in the European Union for the treatment of mild to moderate idiopathic pulmonary fibrosis. Clinical evaluation is based on two double-blind randomised placebo-controlled trials lasting 72 weeks in a total of 779 patients. Mortality, the frequency of exacerbations and the number of lung transplants did not differ significantly between the pirfenidone and placebo groups in either trial. Decline in forced vital capacity was smaller with pirfenidone than with placebo, but the difference was statistically significant in only one of the trials. The small difference in this surrogate endpoint is of questionable clinical relevance. 14.8% of the patients taking pirfenidone 2403 mg/day (maintenance dose according to the marketing authorisation) discontinued treatment because of adverse events, versus 8.6% of patients in the placebo groups. Serious adverse effects included 3 cases of bladder cancer in the pirfenidone groups versus 1 case in the placebo groups. Photosensitivity and skin rash, cardiac arrhythmias and coronary artery disease were more frequent with pirfenidone 2403 mg/day than with placebo. Abnormal transaminase elevation occurred in 4.1% of patients on pirfenidone 2403 mg/day versus 0.6% of patients on placebo. A few cases of acute renal failure were also observed. In practice, there is no evidence that pirfenidone improves quality of life in patients with mild to moderate idiopathic pulmonary fibrosis, or that it slows the progression of pulmonary fibrosis. The adverse effect profile is already burdensome. Pending real therapeutic advance, it is best to avoid pirfenidone altogether and to focus on symptomatic treatment.
 ...
PMID:Pirfenidone. First, do no harm. 2381 68